Information Provided By:
Fly News Breaks for February 12, 2020
Feb 12, 2020 | 05:53 EDT
Citi analyst Yigal Nochomovitz initiated coverage of Ardelyx with a Buy rating and $13 price target. The company is developing lead drug tenapanor for hyperphosphatemia in patients on dialysis, says the analyst, who expects a launch in mid-2021. Tenapanor will gain meaningful market share from phosphate binders in the hyperphosphatemia space, Nochomovitz tells investors in a research note. The analyst's bull case scenario is $22 per share for Ardelyx.
News For ARDX From the Last 2 Days
Dec 1, 2021 | 09:40 EST
Unusual total active option classes on open include: Ardelyx (ARDX), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Vertex Energy (VTNR), 180 Life Sciences (ATNF), XPeng (XPEV), Li Auto (LI), Altimeter Growth Corp (AGC), Cameco (CCJ), and Merck (MRK).
Nov 30, 2021 | 10:39 EST
Piper Sandler analyst Christopher Raymond keeps a Neutral rating on Ardelyx, with a price target of $4, following management's announced plans to launch Ibsrela in IBS-C. FDA approved Ibsrela back in September, 2019, but the opportunity was shelved as management had indicated the undifferentiated clinical profile, coupled with the large expense of launching in this market required that Ardelyx find a partner, the analyst adds. Raymond understands investors may be skeptical of this sequence of events. That said, he is "willing to listen" and thinks it makes sense to do some of his own work on this opportunity.